21 Sep 2012, BioSpectrum Bureau , BioSpectrum
Bangalore: Opto Eurocor Healthcare, a subsidiary of Opto Circuits, launched its first Sirolimus Drug Eluting Stent (DES), E-MAGIC Plus on receipt of Drug Controller General of India (DCGI) license to sell and market the product in India. With the launch of E-MAGIC Plus, Opto Circuits becomes one of the few global players to offer DES products with a choice of two drug coatings.
On the launch of E-MAGIC Plus, Mr Vinod Ramnani, CMD, Opto Circuits, said, " E-MAGIC Plus has been developed indigenously in India and with the DCGI mark we can market and sell in India. The DCGI approval will also enable E-Magic Plus to be marketed in parts of far east and parts of middle east Asia. We trust that E-MAGIC Plus will offer better treatment options and significant therapeutic advantages for the patients."
The Sirolimus DES market is estimated to be worth $14.54 million (Rs800 crore) in India. Opto Eurocor Healthcare will launch E-MAGIC Plus in the European and Latin American market after receiving the necessary approvals.
E-MAGIC Plus consists of a balloon-expandable intra coronary cobalt chromium stent pre-mounted on a custom balloon delivery system with a Sirolimus coating and a biodegradable polymer. The E-MAGIC Plus stent releases a distinctive anti-rejection drug, Sirolimus (also known as Rapamycin), into the arterial wall. Sirolimus helps control excess growth of cells and allows the artery to heal. E-MAGIC Plus stent has an extra edge with soft tip technology to provide smooth access to the lesion site ensuring minimal trauma to the vessel wall.
Opto Eurocor Healthcare is dedicated to the design, development and commercialization of minimally invasive technologies for the treatment of cardiovascular and endovascular diseases. The company houses well known and clinically superior PTA stenting and balloon brands as TAXCOR, DIOR, and FREEWAYTM. It has research centers, sales offices and state-of-the-art manufacturing facilities in Europe and Asia.